Q-Urol
Phase 2Small molecule
Q-Urol is one of 16 small molecule programs targeting Prostatitis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Prostatitis
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Otezla
AmgenApproved
Rapaflo
AbbVieApproved
Keflex
Eli LillyApproved
Lynparza
AstraZenecaApproved
Avodart
Akero TherapeuticsApproved
Uroxatral
AAdvanz Pharma
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Q-Urol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Utah